NUTEX HEALTH REPORTS SEPTEMBER 30, 2025 THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS

Core Insights - Nutex Health Inc. reported a significant financial performance for the three and nine months ended September 30, 2025, with a revenue growth of 225% and a record cash balance of $166 million [5][7]. Financial Highlights for Three Months Ended September 30, 2025 - Total revenue reached $267.8 million, a 239.9% increase from $78.8 million in the same period of 2024 [7]. - Hospital division revenue was $260.2 million, up 262.8% from $71.7 million in Q3 2024 [7]. - Net income attributable to Nutex Health was $55.4 million, compared to a net loss of $8.8 million in Q3 2024 [7]. - EBITDA for the quarter was $91.8 million, a 2014% increase from $4.3 million in Q3 2024 [7]. - Adjusted EBITDA was $98.5 million, compared to $9.7 million in Q3 2024 [7]. - Operating income improved to $130.4 million from $9.7 million in the same quarter of 2024 [7]. Financial Highlights for Nine Months Ended September 30, 2025 - Total revenue for the nine months was $723.6 million, a 225.5% increase from $222.3 million in the same period of 2024 [7]. - Net income attributable to Nutex Health was $59.0 million, compared to a net loss of $9.5 million in the first nine months of 2024 [7]. - EBITDA for the nine months was $142.9 million, a 616.4% increase from $19.9 million in the same period of 2024 [7]. - Adjusted EBITDA reached $243.0 million, compared to $16.1 million in the first nine months of 2024 [7]. - Total visits at the Hospital Division increased to 140,074, up 13.9% from 122,944 in the same period of 2024 [7]. Operational Insights - The company has a strong pipeline for future growth, reflecting continued demand for small hospitals across the country [6]. - Approximately 70% of hospital revenue was attributed to higher acuity claims and success through the Independent Dispute Resolution (IDR) process [7]. - The company has maintained a high collection rate of over 80% on legal determinations won through arbitration [7]. Compliance and Governance - Nutex Health has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the timely filing of its Form 10-Q for the period ended June 30, 2025 [9][10].